OptimizeRx (OPRX) Expected to Announce Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) is expected to post its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect OptimizeRx to post earnings of $0.25 per share and revenue of $30.36 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

OptimizeRx Price Performance

Shares of OptimizeRx stock opened at $4.30 on Tuesday. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.31. The stock has a market capitalization of $79.21 million, a P/E ratio of -3.23 and a beta of 1.31. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The business’s fifty day moving average price is $5.43 and its 200 day moving average price is $5.95.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Lake Street Capital reiterated a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th. B. Riley reduced their price objective on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Stephens assumed coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective on the stock. Stifel Nicolaus reduced their price objective on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Finally, Roth Mkm restated a “buy” rating and set a $16.00 price objective (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.06.

Insider Transactions at OptimizeRx

In related news, CEO William J. Febbo bought 20,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.10% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.